The 2023 Q3 earnings season kicks off tomorrow with major U.S. banks leading the way Despite the bleak backdrop, S&P 500's Q3 earnings outlook is not as bad as expected This...
Despite a long-term downtrend since December 2021, Pfizer's stock may still be undervalued The company is now aiming to establish a stable, growth-oriented model following a year...
Roughly half of the S&P 500 companies have reported Q2 ’23 financial results, and the forward estimate has firmed up a little bit. The 2023 and 2024 calendar year EPS estimates for...
U.S. jobs report, ISM PMI surveys, more earnings in focus. Apple shares are a buy with fiscal Q3 results due on Thursday. Pfizer’s stock is set to struggle amid shrinking...
Earnings season continues, with healthcare companies set to report next week Among them is Pfizer, whose stock has corrected significantly of late Based on the company's strong...
Stagflation remains one of the primary risks for the global economy in 2023. The stock market’s trajectory will continue to be dictated by worries over persistently high...
Dividend contenders are companies that have increased their dividend for between 10 and 24 years. Investors should look for a combination of a low price and an attractive annual...
Pfizer is merging with Seagen in a $43 billion acquisition. Pfizer expects the acquisition to add $10 billion in revenue by 2030; early indications suggest analysts are less...
Global drug spending is set to reach $1.9 trillion by 2027. Pfizer remains well-positioned to capture much of this. A price-to-earnings ratio of just 8.7 suggests the stock is...
Drugmaker Merck's (NYSE:MRK) stock has outperformed its competitors year to date (ytd), rising 30.6%. Pfizer (NYSE:PFE), which I am bearish on, is down 16.9% so far this year. The...